Clinical Trial Update: Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating whether the anti-IL-6 monoclonal antibody tocilizumab influences cardiovascular risk in rheumatoid arthritis patients. The cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Hospital Universitario de Canarias | Conditions: Rheumatoid Arthritis | Phase 4 | Status: UNKNOWN